Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Modulation of immune function occurs within hours of therapy initiation for multiple sclerosis.

Ayers CL, Mendoza JP, Sinha S, Cunnusamy K, Greenberg BM, Frohman EM, Karandikar NJ.

Clin Immunol. 2013 May;147(2):105-19. doi: 10.1016/j.clim.2013.02.015. Epub 2013 Mar 6.

2.

Failure of glatiramer acetate to modify the peripheral T cell repertoire of relapsing-remitting multiple sclerosis patients.

Berthelot L, Miqueu P, Pettré S, Guillet M, Moynard J, Wiertlewski S, Lefrère F, Brouard S, Soulillou JP, Laplaud DA.

Clin Immunol. 2010 Apr;135(1):33-42. doi: 10.1016/j.clim.2009.12.006. Epub 2010 Feb 8.

PMID:
20116333
3.

Longitudinal assessment of immuno-metabolic parameters in multiple sclerosis patients during treatment with glatiramer acetate.

Carrieri PB, Carbone F, Perna F, Bruzzese D, La Rocca C, Galgani M, Montella S, Petracca M, Florio C, Maniscalco GT, Spitaleri DL, Iuliano G, Tedeschi G, Della Corte M, Bonavita S, Matarese G.

Metabolism. 2015 Sep;64(9):1112-21. doi: 10.1016/j.metabol.2015.05.001. Epub 2015 May 8.

PMID:
25986733
4.

Glatiramer acetate-specific human CD8(+) T cells: increased IL-4 production in multiple sclerosis is reduced by glatiramer acetate treatment.

Dressel A, Vogelgesang A, Brinkmeier H, Mäder M, Weber F.

J Neuroimmunol. 2006 Dec;181(1-2):133-40. Epub 2006 Nov 7.

PMID:
17084909
5.

Biological activity of glatiramer acetate on Treg and anti-inflammatory monocytes persists for more than 10years in responder multiple sclerosis patients.

Spadaro M, Montarolo F, Perga S, Martire S, Brescia F, Malucchi S, Bertolotto A.

Clin Immunol. 2017 Aug;181:83-88. doi: 10.1016/j.clim.2017.06.006. Epub 2017 Jun 19.

PMID:
28642148
6.

Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo.

Weber MS, Starck M, Wagenpfeil S, Meinl E, Hohlfeld R, Farina C.

Brain. 2004 Jun;127(Pt 6):1370-8. Epub 2004 Apr 16.

PMID:
15090474
7.

Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis.

Karandikar NJ, Crawford MP, Yan X, Ratts RB, Brenchley JM, Ambrozak DR, Lovett-Racke AE, Frohman EM, Stastny P, Douek DC, Koup RA, Racke MK.

J Clin Invest. 2002 Mar;109(5):641-9.

8.

Fraction of IL-10+ and IL-17+ CD8 T cells is increased in MS patients in remission and during a relapse, but is not influenced by immune modulators.

Peelen E, Thewissen M, Knippenberg S, Smolders J, Muris AH, Menheere P, Tervaert JW, Hupperts R, Damoiseaux J.

J Neuroimmunol. 2013 May 15;258(1-2):77-84. doi: 10.1016/j.jneuroim.2013.02.014. Epub 2013 Mar 19.

9.

Glatiramer acetate (GA) therapy induces a focused, oligoclonal CD8+ T-cell repertoire in multiple sclerosis.

Biegler BW, Yan SX, Ortega SB, Tennakoon DK, Racke MK, Karandikar NJ.

J Neuroimmunol. 2006 Nov;180(1-2):159-71. Epub 2006 Aug 28.

PMID:
16935352
10.

Immune modulation in multiple sclerosis patients treated with the pregnancy hormone estriol.

Soldan SS, Alvarez Retuerto AI, Sicotte NL, Voskuhl RR.

J Immunol. 2003 Dec 1;171(11):6267-74.

11.

CD4+T-bet+, CD4+pSTAT3+ and CD8+T-bet+ T cells accumulate in peripheral blood during NZB treatment.

Frisullo G, Iorio R, Plantone D, Marti A, Nociti V, Patanella AK, Batocchi AP.

Mult Scler. 2011 May;17(5):556-66. doi: 10.1177/1352458510392263. Epub 2010 Dec 21.

PMID:
21177324
12.

Mechanism of action of glatiramer acetate in treatment of multiple sclerosis.

Weber MS, Hohlfeld R, Zamvil SS.

Neurotherapeutics. 2007 Oct;4(4):647-53. Review.

PMID:
17920545
13.

Beneficial effect of glatiramer acetate (Copaxone) on immune modulation of experimental hepatic fibrosis.

Horani A, Muhanna N, Pappo O, Melhem A, Alvarez CE, Doron S, Wehbi W, Dimitrios K, Friedman SL, Safadi R.

Am J Physiol Gastrointest Liver Physiol. 2007 Feb;292(2):G628-38. Epub 2006 Oct 12.

14.

Therapeutic induction of regulatory, cytotoxic CD8+ T cells in multiple sclerosis.

Tennakoon DK, Mehta RS, Ortega SB, Bhoj V, Racke MK, Karandikar NJ.

J Immunol. 2006 Jun 1;176(11):7119-29.

15.

Glatiramer acetate-specific antibody titres in patients with relapsing / remitting multiple sclerosis and in experimental autoimmune encephalomyelitis.

Bomprezzi R, Schafer R, Reese V, Misra A, Vollmer TL, Kala M.

Scand J Immunol. 2011 Sep;74(3):219-26. doi: 10.1111/j.1365-3083.2011.02581.x.

16.

Glatiramer acetate treatment of multiple sclerosis: an immunological perspective.

Racke MK, Lovett-Racke AE.

J Immunol. 2011 Feb 15;186(4):1887-90. doi: 10.4049/jimmunol.1090138. Review.

17.

Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action.

Lalive PH, Neuhaus O, Benkhoucha M, Burger D, Hohlfeld R, Zamvil SS, Weber MS.

CNS Drugs. 2011 May;25(5):401-14. doi: 10.2165/11588120-000000000-00000. Review.

18.

Deferiprone modulates in vitro responses by peripheral blood T cells from control and relapsing-remitting multiple sclerosis subjects.

Sweeney ME, Slusser JG, Lynch SG, Benedict SH, Garcia SL, Rues L, LeVine SM.

Int Immunopharmacol. 2011 Nov;11(11):1796-801. doi: 10.1016/j.intimp.2011.07.007. Epub 2011 Jul 30.

19.

Beneficial effect of co-polymer 1 on cytokine production by CD4 T cells in multiple sclerosis.

Fellay B, Chofflon M, Juillard C, Paunier AM, Landis T, Roth S, Gougeon ML.

Immunology. 2001 Dec;104(4):383-91.

20.

Glatiramer acetate attenuates the pro-migratory profile of adhesion molecules on various immune cell subsets in multiple sclerosis.

Sellner J, Koczi W, Harrer A, Oppermann K, Obregon-Castrillo E, Pilz G, Wipfler P, Afazel S, Haschke-Becher E, Trinka E, Kraus J.

Clin Exp Immunol. 2013 Sep;173(3):381-9. doi: 10.1111/cei.12125.

Supplemental Content

Support Center